

**OTHER TRANSACTION AGREEMENT (OTA)**

OTHER TRANSACTION FOR ADVANCED RESEARCH (OTAR)

BETWEEN

**Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591-6717**

AND

**THE UNITED STATES OF AMERICA  
DEPARTMENT OF HEALTH AND HUMAN SERVICES  
ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE  
200 C Street, S.W.  
WASHINGTON, DC 20515**

CONCERNING

Novel Antibodies against Influenza Virus, Emerging, re-Emerging, and pre-Emerging pathogens

Modification No. 0004

Date: January 31, 2020

PR No.: OS 206444 \$18,693,213; OS 233799 \$19,274,081; OS234612 \$278,812; OS 253326 \$5,751,859

Total Amount of the Agreement: \$54,997,457 (Changed)

Total Estimated Government Funding of the Agreement: \$43,997,965 (Changed)

Total Estimated Recipient Funding of the Agreement: \$10,999,492 (Changed)

Funds Obligated: \$43,997,965 (Changed)

Period of Performance: September 30, 2017 through June 30, 2022 (Changed)

Authority: Section 319L(c) (4) (B) and/or 319L(c) (4) (D) of the Pandemic and All-Hazards Preparedness Act, P.L. 109-417

Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2017, CAN: 1994027  
(b) (4) (CLIN 0001)

Line of Accounting and Appropriation: Object Class 25106, Appropriation Yr: 2017, CAN: 199TWN  
(b) (4) (CLIN 0001)

Line of Accounting and Appropriation: Object Class 25106, Appropriation Yr: 2017, CAN: 1994047  
(b) (4) (CLIN 0001).

Line of Accounting and Appropriation: Object Class 25106, Appropriation Yr: 2017, CAN: 1994044  
(b) (4) (CLIN 0001).

Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2017, CAN: 1994027  
(b) (4) (CLIN 0002)

Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2017, CAN: 199TWLN  
(b) (4) (CLIN 0003)

Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2019, CAN: 199TWRV  
(b) (4) CLIN 0001 and (b) (4) CLIN 0002)

Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2019, CAN: 1992019  
(b) (4) (CLIN 0001)

Line of Accounting and Appropriation: Object Class: 25106; Appropriation Yr: 2020, CAN: 1992020  
(b) (4) CLIN 0001 and (b) (4) CLIN 0002)

**PURPOSE:** The purpose of this modification is to (1) Add funds to CLIN 0001 and 0002 and (2) Replace Attachment 1: SOW revision dated January 31, 2020.

Beginning with the effective date of this modification, the Government and Other Transaction Agreement holder mutually agree as follows:

1. Agreement No.:  
HHSO100201700020C Line Items  
and corresponding values:

Funding for this OTA is revised as follows:

Line Item	Recipient Cost-Share	Government Cost-Share	Total Estimated Cost	Total Government Funds Obligated to Date
0001 - Base Period	(b) (4)			\$12,561,910
0002 - Option 1				\$22,947,315
0003 - Option 2				\$ 8,488,740
0004 - Option 3				
0005 - Option 4				-
0006 - Option 5				-
Total:				\$43,997,965

Note:

- (i) Internal Expenses. Internal expenses will be determined based on actual labor hours for the activities performed, multiplied by a single, fully-burdened FTE rate not subject to true-up, calculated for the Research & Development organization which will be working on the programs under this Agreement. This rate will be adjusted annually based on the CPI adjustment methodology outlined in the final cost proposal. The Contracting Officer will request documents supporting adjustments in the CPI.
- (ii) External (Subrecipient or Affiliates) Expenses. External expenses will be billed based on actual third-party charges submitted to Regeneron.
- (iii) Drug Supply. Drug supply manufactured at a Regeneron facility will be billed based on a fully-allocated cost methodology which includes direct variable, direct fixed and indirect cost

allocations (See the 9/14/17 proposal). Drug manufactured by a third party contract manufacturer will be billed based on actual third party charges submitted to Regeneron.

- (iv) G&A. G&A expenses will be billed for external expenses and drug supply based on a set rate not subject to true-up. A negotiated rate agreement or rate documentation shall be provided in the subrecipient agreement.

2. Attached are the following documents which support the modified CLIN 0001 and 0002:

- 1) Delete and replace Attachment 1 – Revised Statement of Work (SOW) dated January 31, 2020 18 pages)

All other terms and conditions remain the same.

*FOR THE UNITED STATES OF AMERICA  
OFFICE OF ACQUISITION MANAGEMENT,  
CONTRACTS & GRANTS SECRETARY  
FOR PREPAREDNESS AND RESPONSE*

\_\_\_\_\_  
(Signature) (Date)  
Carl A. Newman,  
Other Transaction Agreement Officer

FOR Regeneron Pharmaceuticals, Inc.

\_\_\_\_\_  
(Signature) (Date)  
Robert E. Landry,  
Executive Vice President, Finance and Chief Financial Officer, Regeneron Pharmaceuticals, Inc.

END OF MODIFICATION No. 0004 TO HHSO100201700020C